All In Biotech

Drug Trial Radar · NCT00251004

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

Efficacy and Safety Study Comparing Concentration-controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients

Last checked: Nov 20, 2026Latest source record: May 10, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 833 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

833

Actual

Start

Oct 2005

Primary completion

Aug 2009

Study completion Oct 2009

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
Nov 9, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to compare the safety and efficacy of three immunosuppressive treatment regimens following a kidney transplant.

Conditions

  • Kidney Transplantation
  • Graft Rejection

Interventions

  • EverolimusDrug

    oral, bis in diem/twice a day (bid)

  • Mycophenolic Acid (MPA)Drug

    2 oral capsules of mycophenolic acid 360mg administered bid

  • Cyclosporine A (CsA)Drug

    CsA dose adjustments were based on CsA trough levels (C0).

  • BasiliximabDrug

    All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.

  • CorticosteroidsDrug

    Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Composite Efficacy Endpoints - 12 Month AnalysisTime frame: 12 months
  2. Non-inferiority Analysis on Percentage of Participants With Composite Efficacy EndpointsTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novartis

    East Hanover, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.